Most authors and studies on early ovarian cancer define "early" ovarian cancer as stage I and stage I of FIGO staging. The question of whether early ovarian cancer needs adjuvant chemotherapy has been debated for decades, but some aspects remain unresolved.
Some early experiments confirmed that some substages of stage I had a good prognosis and a low risk of cancer recurrence and death, so they were classified as a "low-risk group". Follow-up studies usually divide early ovarian cancer into low-risk group and high-risk group.In 1994, the National Institutes of Health (the National Institutes of Health, NIH) held a meeting and reached a consensus on some issues related to ovarian cancer that had sufficient evidence at that time. They believed that the most effective adjuvant therapy could not be confirmed. The team also recommended that patients in the high-risk group of stage I should participate in clinical trials to determine whether adjuvant chemotherapy can improve survival.The recommendations of the National Institutes of Health (NIH) point out that histological grading plays an important role in the prognosis of early cancer. Although numerous studies have shown a correlation between histological grading and prognosis, FIGO staging does not include histological grading in staging.In any case, histological grading has an impact on the design and management of clinical trials.
